Cullinan Therapeutics
Most recent annual filing: 2026-03-15
- CLN-049 Ph2 readout4Q 2026CLN-049 Ph2 readout, 4Q 2026, notable
- CLN-978 readoutDec 2026CLN-978 readout, Dec 2026, material
- Velinotamig trial startearly 2027Velinotamig trial start, early 2027, routine
- Zipalertinib EGFR FDA decisionFeb 27, 2027Zipalertinib EGFR FDA decision, Feb 27, 2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (10 active programs)
velinotamig
CLN-049
zipalertinib
CLN-081 · TAS6417 Small Molecule Target: EGFR, EGFR exon 20 insertion
Discontinued (7)
- CLN-978 — B-Cell Non-Hodgkin Lymphoma · development of CLN-978 in relapsed/refractory B-NHL was discontinued in early 2024
- CLN-619 — Endometrial Cancer · discontinuation of further development of CLN-619 in patients with gynecological cancers as preliminary results did not meet internal threshold for advancement
- CLN-619 — Cervical Cancer · discontinuation of further development of CLN-619 in patients with gynecological cancers as preliminary results did not meet internal threshold for advancement
- CLN-619 — Non-Small Cell Lung Cancer · In November 2025, after a review of the emerging clinical data in patients with NSCLC and multiple myeloma, we discontinued further development of CLN-619.
- CLN-619 — Multiple Myeloma · In November 2025, after a review of the emerging clinical data in patients with NSCLC and multiple myeloma, we discontinued further development of CLN-619.
- CLN-617 — undisclosed · In November 2025, after a review of the emerging clinical data in patients with advanced solid tumors, we discontinued further development of CLN-617.
- CLN-418 — undisclosed · discontinued development of CLN-418 and returned development and commercial rights for CLN-418 to Harbour
Biotech Distilled coverage (12)
- 2026-10-02 UPDATE: Cullinan Therapeutics (CGEM) - The Frontline Filing Jumps the Line ★ Distilled Pro
- 2026-09-24 UPDATE: Cullinan Therapeutics (CGEM) - The Q3 Print Slides to December 🔒 Paid
- 2026-09-15 UPDATE: Cullinan Therapeutics (CGEM) - The Hazard Ratio Finally Shows Up 🔒 Paid
- 2026-08-14 UPDATE: Cullinan Therapeutics (CGEM) - The Safety Net Turns Into a Second Engine 🔒 Paid
- 2026-07-28 UPDATE: Cullinan Therapeutics (CGEM) - The AML Hammer Gets a Regulatory Runway 🔒 Paid
- 2026-06-10 UPDATE: Cullinan Therapeutics (CGEM) - The Second Leg Lands
- 2026-06-08 UPDATE: Cullinan Therapeutics (CGEM) - The Full Poster Lands, the Stock Sells the News
- 2026-05-19 UPDATE: Cullinan Therapeutics (CGEM) - The Abstract Drop Front-Runs EULAR 🔒 Paid
- 2026-05-08 UPDATE: Cullinan Therapeutics (CGEM) - The Catalyst Has a Date and a Stage 🔒 Paid
- 2026-04-29 UPDATE: Cullinan Therapeutics (CGEM) - The PDUFA Lands, the ATM Opens 🔒 Paid
- 2026-03-14 UPDATE: Cullinan Therapeutics (CGEM) - A 14% Haircut on Housekeeping Filings 🔒 Paid
- 2026-01-22 Cullinan Therapeutics (CGEM): Scientific Deep Dive for CLN-978 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.